List/Grid

Oncology Subscribe to Oncology

Treatment developed by biologists shows promise in fighting fibrotic disease

Treatment developed by biologists shows promise in fighting fibrotic disease

A decade after first identifying serum amyloid P (SAP) as a key protein in human blood that controls routine tissue-related processes from scarring to healing, two Texas A&M University scientists and the biotechnology company they co-founded continue to make encouraging progress in the fight against fibrotic disease, a broad class of chronic conditions associated with an estimated 45 percent of U.S. deaths per year. Texas A&M biologists Richard Gomer and Darrell Pilling have collaborated in recent years on several SAP-related advances, from establishing Promedior Inc Continue reading

Bone tumour destroyed using incisionless surgery: First in North American child

Bone tumour destroyed using incisionless surgery: First in North American child

A patient at The Hospital for Sick Children (SickKids) is the first child in North America to have undergone a specialized procedure that uses ultrasound and magnetic resonance imaging (MRI) to destroy a tumor in his leg without piercing the skin. Doctors used an MRI to guide high-intensity ultrasound waves to destroy a benign bone tumor called osteoid osteoma. Continue reading

Many cancer survivors smoke years after diagnosis

Many cancer survivors smoke years after diagnosis

Nine years after diagnosis, 9.3 percent of U.S. cancer survivors were current smokers and 83 percent of these individuals were daily smokers who averaged 14.7 cigarettes per day, according to a report in Cancer Epidemiology, Biomarkers & Prevention , a journal of the American Association for Cancer Research (AACR). Continue reading

Genetic cause of common breast tumors found

Genetic cause of common breast tumors found

A multi-disciplinary team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, and Singapore General Hospital have made a major breakthrough in understanding the molecular basis of fibroadenoma, one of the most common breast tumors diagnosed in women. Continue reading

Targets for immunotherapy in early-stage breast cancer

Targets for immunotherapy in early-stage breast cancer

Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. The diagnostic test, using RNAScope, measures the amount of PD-L1 (programmed death ligand 1) mRNA in routine formalin-fixed cancer tissues and is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. PD-L1 is the target of several novel immune stimulatory therapies in clinical trials Continue reading

Wake-up call for more research into cell metabolism

Wake-up call for more research into cell metabolism

More scientific research into the metabolism of stromal support cells and immune cells — and the role of the metabolism of these cell types in the development of diseases — could open new therapeutic avenues for diabetes, inflammatory conditions and cancer. That was the conclusion of a review article by scientists from VIB and KU Leuven in the leading journal Nature Continue reading

Proton therapy has advantages over IMRT for advanced head, neck cancers

Proton therapy has advantages over IMRT for advanced head, neck cancers

A new study by radiation oncologists at Mayo Clinic comparing the world’s literature on outcomes of proton beam therapy in the treatment of a variety of advanced head and neck cancers of the skull base compared to intensity modulated radiation therapy (IMRT) has found that proton beam therapy significantly improved disease free survival and tumor control when compared to IMRT. Continue reading

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. “The CALGB/SWOG 80405 trial was designed and formulated in 2005, and the rationale was simple: we had new drugs –bevacizumab and cetuximab– and the study was designed to determine if one was better than the other in first-line for patients with colon cancer,” said lead study author Alan P. Venook, distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco, USA Continue reading

Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies

Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies

The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. “Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies,” said Takayuki Yoshino of the National Cancer Centre Hospital East in Chiba, Japan, lead author of the phase III RECOURSE trial. Continue reading

False negative results found in prognostic testing for breast cancer

False negative results found in prognostic testing for breast cancer

A recent study evaluating HER2 testing in a large cohort of women with breast cancer found important limitations in the conventional way HER2 testing is performed in the US and internationally. Dartmouth-Hitchcock Norris Cotton Cancer Center physicians and researchers retested tumor samples from a large group of women and found that 22 out of 530 women had their tumor type incorrectly classified Continue reading